Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2021 | $56.00 | Outperform → Mkt Perform | Keefe Bruyette |
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that the Company's common stockholders, at a special meeting of the Company's common stockholders held earlier today (the "Special Meeting"), voted to adopt the previously announced merger agreement for the acquisition of the Company by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement, the Company's common stockholders will be entitled to receive $56.00 per share in cash at the closing of the acquisition. The transaction is expected to close in the late third quarter or early fourth quarter of 2021. Upon completion of the acqui
CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co
Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count
SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
424B4 - Caris Life Sciences, Inc. (0002019410) (Filer)
Keefe Bruyette downgraded CAI Intl from Outperform to Mkt Perform and set a new price target of $56.00
William Blair downgraded CAI International from Outperform to Market Perform
B. Riley Securities downgraded CAI International from Buy to Neutral
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)